Developing an Alternative to Opioids for Post-Surgical Pain

Episode Summary

Executive Summary: The episode features LA Therapeutics CEO Adam Gridley discussing the company’s non-opioid approach to post-surgical pain, centered on ATX 101, an implanted, extended-release bupivacaine polymer for knee replacement. Gridley argues the unmet need is large for patients, surgeons, and payers, and says the platform could expand to shoulder, hip, spine, and other surgeries if ongoing trials continue to validate safety, efficacy, and ease of use.

Main Topics: The unmet need for non-opioid post-surgical pain control (Priority: 5/5): Gridley frames post-operative pain as a major clinical and economic problem, especially because opioids are still widely used after surgery and can lead to dependence, adverse events, and chronic use. Why total knee arthroplasty is the lead indication (Priority: 5/5): LA Therapeutics chose total knee replacement because pain lasts longer than current local analgesics, creating a 'therapeutic gap' where opioids remain the default despite known risks. ATX 101 design and mechanism (Priority: 5/5): ATX 101 is a triangle-shaped, guitar-pick-sized polymer implant placed during surgery to release bupivacaine over about 30 days, aiming to match the patient's pain curve. Clinical evidence and trial progress (Priority: 5/5): The company reports promising early studies, including controlled release, reduced pain, lower opioid use, improved function and sleep, and ongoing pivotal trials with readout expected later in 2025. Platform potential beyond knee replacement (Priority: 4/5): LA Therapeutics plans to adapt its foundational polymer technology to other durations, procedures, and drugs, including shoulder/hip surgery, soft-tissue procedures, and injectable nerve-block products. Manufacturing, workflow, and surgeon adoption (Priority: 4/5): A core design goal was simplicity: quick placement, no special training, no refrigeration, and minimal added procedure time, to improve surgeon adoption and fit existing operating-room workflow. Financing and commercialization timeline (Priority: 3/5): A recent Series D financing supports operations into 2026, with additional fundraising expected after upcoming trial data and a potential FDA filing/approval pathway stretching into 2028 and beyond.

Key Arguments: Post-surgical pain is a large unmet need because opioids are still the dominant bridge therapy after surgery, yet they carry dependence and abuse risks. Knee replacement is the right first market because pain persists for 3-4 weeks while many long-acting analgesics last only days, leaving a major therapeutic gap. Bupivacaine is an established, familiar analgesic; the innovation is not the drug itself but controlled, extended release from an implanted polymer. ATX 101 is designed to be simple for surgeons to place, saving time versus standard approaches and avoiding complex handling or training. Early clinical data suggest the product can reduce pain, lower opioid consumption, and improve sleep and function, which are meaningful patient-centered outcomes. The company sees a broader platform opportunity by altering polymer, drug, dose duration, and implant shape for different surgeries and pain durations. Investor interest was driven by strong clinical data, a large market, workflow efficiency, and alignment with payer pressure to reduce healthcare costs and opioid burden.

Data Points: Americans prescribed opioids after surgery annually: about 50 million - Estimated number of U.S. patients receiving opioids for post-surgical pain each year Persistent opioid users after surgery: greater than 2.5 million - Patients who progress to persistent opioid use after surgical opioid exposure Core target market procedures: about 30 million painful surgical procedures - Includes orthopedics, general, abdominal, gynecological, cardiac, and plastic surgery Market opportunity: about $10 billion - Estimated opportunity across key painful surgical procedures Duration of knee pain: 3 to 4 weeks - Pain duration after total knee arthroplasty that motivates the lead indication Current long-acting local analgesic duration: 2 to 3 days - Existing competitors’ typical duration, creating the therapeutic gap Opioid dependence onset: 3 to 5 days - Risk window after short-term opioid exposure TKA patients still using opioids at two weeks: half - Illustrates persistence of opioid use after knee replacement Dissatisfaction rate after surgery: as high as 20% - Patient dissatisfaction with current post-knee-replacement pain management Annual healthcare costs tied to addiction: over $20 billion - Costs associated with addiction, attributed here to post-operative pain Lives lost to drug overdoses (2020-2024): greater than 500,000 - Broader overdose burden discussed in relation to opioids Share of overdose deaths involving opioids: 75% - Prescription or illicit opioids Patients progressing to chronic post-surgical pain: an estimated 20 million - Estimated chronic pain burden after surgery Relative risk of chronic pain after orthopedic surgery: nearly 3-fold - Compared with other procedures ATX 101 dose per implant: 500 mg - Each triangle-shaped implant dose Number of implants used: 3 - Placed at the end of surgery for a total dose Total studied dose: 1500 mg - Combined ATX 101 dose used in clinical trials Administration time saved: 5 to 10 minutes - Compared with standard of care or competitor products Drug release duration: about 30 days - ATX 101 dissolves over roughly a month Clinical development duration: over 5 years - Length of the company’s clinical program Exploratory studies completed: 2 - Dose-range-finding studies outside the United States Pivotal registration studies: 2 - The first started in February 2025; another is planned Patient enrollment in current pivotal study: 225 patients - Study expected to report results later in 2025 Series D financing: $57.5 million - Raised in June to support development Cash runway: into the third quarter of 2026 - How long existing cash is expected to last Expected FDA approval timing: mid-2028 - Company’s projected approval target for ATX 101

Pivotal Quotes: "Surgery is often described as the gateway to the opioid epidemic." — Adam Gridley: Explaining why post-surgical pain management is such an important public health issue "We designed the product with first-order kinetics, where ATX 101 has controlled dosing, and we deliver more drug in the first week when the patient's pain is the highest and they're trying to start their recovery, and then less overtime with all of the drug being gone at 30 days." — Adam Gridley: Describing the release profile of the implanted polymer and how it matches the pain journey "We wanted to be able to place these into natural gutters or pockets that exist in the knee capsule, and thereby avoiding additional cutting or disruption of the tissue." — Adam Gridley: Explaining the implant’s geometry and surgical placement strategy

Implications: If validated in pivotal studies, LA Therapeutics could offer a practical opioid-sparing standard for surgery, first in knee replacement and later across multiple procedures, potentially improving recovery while reducing addiction risk and costs.